What's Hot
View all perspectives
Intervention in individuals predisposed to develop rheumatoid arthritis (RA), with a holy grail of prevention of RA, has long been a hot topic. It is well known that seropositivity for rheumatoid factor and antibodies to cyclic citrullinated peptides (ACPA) can precede RA disease by many years. Many, but by no means all, patients also seem to go through a pre-RA arthalgia phase of varying duration characterised by the presence of increasing
Robert B Chao, MD doctorRBC
2 years 5 months ago
Important to capture MDA in the first year! Failure to achieve MDA in 1st year after PsA diagnosis associated with worse quality of life persisting despite intensified treatment.
@RheumNow #EULAR2022 ABST#OP0028 https://t.co/FrO569J10S
Eric Dein ericdeinmd
2 years 5 months ago
#EULAR2022 OP0071
Association between long-term exposure to air pollution (fine particulate matter) and immune-mediated disease in Italy
⭐️⬆️ risk of autoimmune disease, esp RA as well as CTD, IBD
⭐️Every 10 ug/m3 increase in PM, associated with incremental 7% risk
@RheumNow https://t.co/x57CXUHSHb
Eric Dein ericdeinmd
2 years 5 months ago
#EULAR2022 Updated ANCA Vasculitis Recommendations
⭐️Incorporates PEXIVAS and ADVOCATE findings
⭐️EGPA guidelines
⭐️PJP PPx recommendations
https://t.co/CnMnxTlB1D
@Rheumnow
Robert B Chao, MD doctorRBC
2 years 5 months ago
No longer a "seronegative" disease?
Serological collagen biomarkers (degradation markers of type I and VI collagen) can differentiate PsO pts from PsA.
Potential biomarkers of MSK involvement?
@RheumNow #EULAR2022 ABST#OP0031 https://t.co/vS6mD5PUxw
Robert B Chao, MD doctorRBC
2 years 5 months ago
6 psoriatic disease specific risk factors associated with incident cardiovascular events in PsA/PsO patients: PsO area, TJC, SJC, HAQ score, ESR, daily use of NSAIDs
@RheumNow #EULAR2022 #ABSTOP0030
At EULAR 2022, I look forward to key topics and presentations in psoriatic arthritis (PsA). Here's a preview of nine studies I'm particularly interested in at this meeting.
Aurelie Najm AurelieRheumo
2 years 5 months ago
NORD-STAR substudy of coagulation and fibrinolytic parameters:
〽️Impairement in eRA
⚡️Biologic parameters restored by ttmt.
Effect seemed ▶️ with Biologic vs. MTX + GCs
❕No adjustment on disease activity #OP0059 #EULAR2022 @RheumNow https://t.co/CJHldOimBn
Aurelie Najm AurelieRheumo
2 years 5 months ago
🚨 Depression = major comorbidity!
DANBIO register 10000+ patients:
❗️10% prescription antidepressants💊
❗️Cumulative mortality ⬆️ w/ OR>6
❗️Particularly in age group <55
#OP0067 #EULAR2022 @RheumNow https://t.co/le8VWBFjPK
Richard Conway RichardPAConway
2 years 5 months ago
Silverio-Antonio et al. Predictors of ILD development in MCTD. Older age at diagnosis (OR 1.1) and lymphadenopathy at presentation (OR 19.65)! predictors @RheumNow #EULAR2022 POS0901 https://t.co/IJ8Vcaga8o
TheDaoIndex KDAO2011
2 years 5 months ago
Continue with PJP prophylaxis during the 6 months of induction Rx and until B cells repleted and if prednisone > = 20 mg/day #EULAR2022 AAV reccs @rheumnow
Dr. John Cush RheumNow
2 years 5 months ago
RheumNow’s expanded coverage of the #EULAR2022 annual meeting is sponsored in part by Bristol-Myers Squibb. All content is chosen by RheumNow & its Faculty.
Poster Hall